EUVIMEDEUVIMED entdecken
Crossref

Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System

Katsuhiro Ohyama, Nonoka Abe, Takumi Okamoto, Yusuke Hori

Int. Journal of Clinical Pharmacology and Therapeutics · 01.01.2026 · 64 (01) · 1-8

DOI: 10.5414/cp204789 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, erschienen am 01.01.2026. Verfasst von Katsuhiro Ohyama und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fractures, Bone, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Fractures, BoneGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsPioglitazoneAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedIncretinsPharmacovigilanceAdverse Drug Reaction Reporting Systems

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsIncretinsPioglitazone

Zitieren

APA

Ohyama, K., Abe, N., Okamoto, T., & Hori, Y. (2026). Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System. Int. Journal of Clinical Pharmacology and Therapeutics, 64(01), 1-8. https://doi.org/10.5414/cp204789

Vancouver

Ohyama K, Abe N, Okamoto T, Hori Y. Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System. Int. Journal of Clinical Pharmacology and Therapeutics. 2026;64(01):1-8. doi:10.5414/cp204789

BibTeX
@article{Ohyama2026,
  author = {Ohyama, Katsuhiro and Abe, Nonoka and Okamoto, Takumi and Hori, Yusuke},
  title = {Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System},
  journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
  year = {2026},
  volume = {64},
  number = {01},
  pages = {1--8},
  doi = {10.5414/cp204789}
}
Kostenlos starten →